Fractional Resurfacing Device for Treatment of Acne Scarring

Acne Clinical Trial

Official title:

Evaluation of a Novel Fractional Resurfacing Device for the Treatment of Acne Scarring

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00585286
• Other study ID #: 2006-5328
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: December 26, 2007
• Last updated: December 13, 2013
• Start date: March 2007
• Est. completion date: July 2008

Study information

• Verified date: December 2013
• Source: University of California, Irvine
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate the safety and effectiveness of a new investigational laser device for treatment of acne scarring, for improvement in the appearance of surface texture and topography (recessed or uneven surfaces).

Description:

Thirty subjects between two research locations with an acne scar severity score greater than 4 will receive up to 3 treatments with an FDA IDE and Institutional Review Board approved 10,600nm fractional carbon dioxide laser system. Improvement of acne scarring is evaluated at 1 month and 3 months post-treatment.

Post-treatment responses evaluated are immediate erythema, immediate edema, and any other immediate responses. Evaluations are conducted immediate post treatment and one week post-treatment. Key safety data include the severity scoring of post-treatment responses, as well as by photodocumentation.

The incidence of side effects such as scarring, pigmentary changes, etc. are evaluated at follow-up visits one and three months post-treatment. Key safety data include the incidence rates and severity scoring of side effects, as well as by photodocumentation

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: July 2008
• Est. primary completion date: July 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Have Fitzpatrick skin type I-V. (Type I is blonde/red hair with freckles and Type V are Hispanics and lighter African Americans.)

• Are male or female.

• Are between 18 and 75 years of age.

• Have moderate to severe acne scarring. Acne scarring will be assessed with the Acne Scar Severity Scale. Subjects will be eligible for treatment if the area to be treated is scored as having an Acne Scar Severity Score > 4 according to the Acne Scar Severity Scale (0-9).

• Are able to read, understand, and sign the Informed Consent.

• Are willing and able to comply with all follow-up requirements for a minimum of 8 months.

Exclusion Criteria:

• Have had active localized or systemic infections within 6 months of enrollment

• Have compromised ability for wound healing, such as: malnutrition, oral steroid use, history of collagen vascular disease (e.g. lupus, scleroderma, history of keloid formation (raised and thickened scars), atrophic dermatitis (extreme skin irritation or itchiness) or immunologic abnormalities such as vitiligo (white patches of skin due to loss of pigment)

• Have immunocompromised status (inability to resist infection, etc.)

• Have been treated with lasers, chemical procedures, or other cosmetic procedures on the area to be treated within 6 months of enrollment

• Have taken Accutane within 12 months of enrollment

• Are allergic to lidocaine (skin numbing agent)

• Are allergic to Valtrex (an anti-viral medication)

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acne
• Scar

Intervention

Device:
• 10,600 nm fractional carbon dioxide laser system
1-3 laser treatments using 20-100 millijoules (mJ) with 100-400 microscopic treatment zones (MTZ)/cm2 per pass and total density of 600-1200 MTZ/cm2

Locations

Country	Name	City	State
United States	UC Irvine Dermatology Clinical Research Center	Irvine	California

Sponsors (3)

Lead Sponsor	Collaborator
University of California, Irvine	Reliant Technologies, Inc. Mountain View, CA, University of Minnesota - Clinical and Translational Science Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Improvement of Acne Scarring	Subject assessment of the percent improvement of acne scarring compared to baseline and based on the quartile scale (0: no improvement; 1: 1-25% improvement; 2: 26-50%; 3: 51-75%; 4: 76-100% improvement).	Baseline, 1 month and 3 months post-treatment	Yes
Primary	Average Improvement in Surface Texture	Subject assessment of the percent improvement of surface texture compared to baseline and based on the quartile scale (0: no improvement; 1: 1-25% improvement; 2: 26-50%; 3: 51-75%; 4: 76-100% improvement).	Baseline, 1 month and 3 months post-treatment	No
Primary	Degree of Atrophy	Subject assessment of the percent improvement in extent of atrophy compared to baseline and based on the quartile scale (0: no improvement; 1: 1-25% improvement; 2: 26-50%; 3: 51-75%; 4: 76-100% improvement).	Baseline, 1 month and 3 months post-treatment	No
Secondary	Pain Tolerance	The average pain score reported over all three treatments was 5.67, corresponding to "moderate" pain based on a 10-point scale. The pain score is recorded on a 10-point scale, with 0 being "no pain" and 10 being "worst pain imaginable." All subjects reported that any discomfort associated with the procedure was only during active intervention and resolved immediately post-procedure. Increased pain scores correlated with increased density, but not increased energy.	At treatment visit (up to 3 visits)	Yes

External Links

•   University of California, Irvine Department of Dermatology Clinical Research